Elektrofi

Elektrofi is a private, Boston-based biotech company founded in 2018, specializing in advanced drug delivery platforms. Its proprietary Hypercon™ microparticle technology enables the ultra-high concentration of biologic drugs, facilitating patient-friendly subcutaneous administration instead of lengthy IV infusions. The company has secured significant partnerships with major pharmaceutical firms like Janssen and Eli Lilly and recently closed a substantial $112.25 million Series C financing to scale manufacturing and advance clinical programs. Elektrofi operates as a platform technology company, driving a portfolio of partnered programs toward clinical development.

Hypercon™: A proprietary hyper-concentration microparticle platform that enables the formulation of high-dose biologic drugs into low-volume, stable suspensions for subcutaneous injection, achieving concentrations up to 500 mg/mL.

Elektrofi competes in the high-concentration subcutaneous delivery space with companies like Halozyme (ENHANZE®), which uses a recombinant hyaluronidase enzyme, and other firms developing viscosity-reducing excipients or alternative formulation technologies. Its microparticle approach offers a differentiated mechanism to achieve ultra-high concentrations.